We are live on ! Find out more
PTGX icon

Protagonist Therapeutics
PTGX

128 hedge funds and large institutions have $875M invested in Protagonist Therapeutics in 2020 Q4 according to their latest regulatory filings, with 46 funds opening new positions, 48 increasing their positions, 21 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

360% more first-time investments, than exits

New positions opened: 46 | Existing positions closed: 10

129% more repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 21

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

39% more funds holding

Funds holding: 92 → 128 (+36)

20% more capital invested

Capital invested by funds: $728M → $875M (+$147M)

12.12% more ownership

Funds ownership: 101.29% → 113.41% (+12%)

76% less call options, than puts

Call options by funds: $214K | Put options by funds: $901K

Holders
128
Holders Change
+36
Holders Change %
+39.13%
% of All Funds
2.27%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.05%
New
46
Increased
48
Reduced
21
Closed
10
Calls
$214K
Puts
$901K
Net Calls
-$687K
Net Calls Change
-$681K

Top Buyers

Rank Fund Capital Flow
1
BI
BVF Inc
California
+$40.9M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$26.9M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
+$11.8M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$10M
5
CCM
Consonance Capital Management
New York
+$7.75M

Top Sellers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$29.5M
2
FCM
Farallon Capital Management
California
-$6.99M
3
SI
Sofinnova Investments
California
-$6.99M
4
Renaissance Technologies
Renaissance Technologies
New York
-$6.48M
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$4.11M
Name Holding Trade Value Shares
Change 		Change in
Stake
TLP
26
Tri Locum Partners
New York
$5.23M +$5.58M +259,283 New
PAM
27
Panagora Asset Management
Massachusetts
$4.77M +$1.68M +77,828 +49%
Charles Schwab
28
Charles Schwab
California
$4.54M +$188K +8,734 +4%
PA
29
Perceptive Advisors
New York
$4.1M +$4.38M +203,591 New
ACM
30
Altium Capital Management
New York
$3.75M +$4M +185,854 New
Two Sigma Investments
31
Two Sigma Investments
New York
$3.15M -$1.37M -63,837 -29%
IBT
32
International Biotechnology Trust
United Kingdom
$3.06M – – –
TLCM
33
Twin Lakes Capital Management
California
$2.87M +$3.07M +142,483 New
Bank of Montreal
34
Bank of Montreal
Ontario, Canada
$2.75M +$2.84M +132,169 +9,407%
AG
35
Artal Group
Luxembourg
$2.68M – – –
LCM
36
Laurion Capital Management
New York
$2.62M +$2.8M +130,158 New
Bank of New York Mellon
37
Bank of New York Mellon
New York
$2.61M +$750K +34,850 +37%
Marshall Wace
38
Marshall Wace
United Kingdom
$2.35M +$2.51M +116,794 New
AI
39
Atom Investors
Texas
$2.01M +$1.9M +88,473 +780%
MS
40
Maven Securities
Jersey
$1.81M +$1.94M +90,000 New
Swiss National Bank
41
Swiss National Bank
Switzerland
$1.67M +$1.78M +82,700 New
California Public Employees Retirement System
42
California Public Employees Retirement System
California
$1.52M +$8.18K +380 +0.5%
GTCM
43
Gyon Technologies Capital Management
New Jersey
$1.5M +$1.61M +74,652 New
Allianz Asset Management
44
Allianz Asset Management
Germany
$1.5M – – –
Wells Fargo
45
Wells Fargo
California
$1.48M +$1.02M +47,287 +180%
MIM
46
Monashee Investment Management
Massachusetts
$1.41M +$1.51M +70,000 New
Ameriprise
47
Ameriprise
Minnesota
$1.35M +$1.44M +66,855 New
UBS Group
48
UBS Group
Switzerland
$1.31M +$225K +10,445 +19%
EGI
49
EAM Global Investors
California
$1.25M -$953K -44,288 -42%
MWNA
50
Marshall Wace North America
New York
$1.23M +$1.31M +61,048 New
1
2
3 4 5

PTGX Hedge Fund Activity: Q4 2020 in Review

128 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q4 2020, worth a combined $875M — up 20% from $728M a quarter earlier.

Buyers outnumbered sellers: 46 funds opened new PTGX positions and 10 closed out — a net gain of 36 holders — while 48 added to existing stakes and 21 trimmed.

The largest buyer was BVF Inc, adding an estimated $40.9M. The largest seller was Adage Capital Partners, cutting an estimated $29.5M.

  • 128 institutional investors held Protagonist Therapeutics (PTGX) as of Q4 2020, up from 92 in Q3 2020.
  • Funds reported $875M of Protagonist Therapeutics stock for Q4 2020, up 20% quarter-over-quarter.
  • 46 funds opened new Protagonist Therapeutics positions in Q4 2020 and 10 closed out, a net change of +36 holders.
  • The largest Protagonist Therapeutics buyer in Q4 2020 was BVF Inc, an estimated $40.9M added.
  • The largest Protagonist Therapeutics seller in Q4 2020 was Adage Capital Partners, an estimated $29.5M sold.

Based on aggregated 13F filings for Q4 2020.